Seven Research Peptides Head to the FDA July 2026 Advisory Committee: A Chemical Identity Primer

The FDA has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for 23-24 July 2026 to review a set of peptides previously placed under compounding restriction. Legal analyses published in the current window — including a 5 May 2026 client alert from Foley and Lardner — identify the substances under review as BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon, each to be considered in free-base and acetate-salt forms. This article is a chemical-identity primer on those seven; it does not address use, dosing or efficacy.

A point repeatedly stressed in the legal commentary is that moving a substance off a do-not-compound category, or scheduling it for advisory review, is not FDA approval and is not a safety or efficacy endorsement. The reviewers note that several of these peptides have limited published clinical characterization. From a verification standpoint, regulatory category and analytical identity are independent axes: a change in the former does not alter what must be measured to confirm the latter.

The table below summarizes each peptide by class and approximate average molecular weight of the free base. Values are nominal reference figures for the canonical sequence; the salt form supplied changes the measured mass and the net peptide content, which is precisely why identity must be confirmed analytically rather than inferred from a name.

The TB-500 row is deliberately qualified. Material sold under that name is not a single defined entity across sources — some correspond to a short synthetic actin-binding fragment, others to the full 43-residue thymosin beta-4. That ambiguity is itself a verification problem: the same trade name can map to chemically distinct molecules with different masses.

Synthetic peptides are typically isolated as salts. Acetate and trifluoroacetate (TFA) are the most common counter-ions from purification. The PCAC is reviewing free-base and acetate forms as distinct entries because they are, chemically, distinct substances: same peptide cation, different counter-ion, different formula mass, and different net peptide content per milligram of powder.

A vial labeled by total powder mass is not equivalent to the same mass of free-base peptide. Counter-ion mass, residual water and residual purification solvents all reduce the fraction that is peptide. A credible characterization therefore reports salt form, net peptide content and counter-ion identity, not only a chromatographic purity percentage. Two lots with identical purity figures can differ materially in actual peptide content if their salt forms or water content differ.

• Identity by mass spectrometry: observed monoisotopic or average mass matched to the declared sequence and salt form.
• Sequence confirmation where the trade name is ambiguous (notably TB-500-type material).
• Chromatographic purity (typically RP-HPLC) with the method and wavelength stated.
• Counter-ion and net peptide content, so milligram figures are interpretable.
• Water content and residual solvents, which affect mass balance.
• Lot-specific reporting — a generic specification sheet is not a lot Certificate of Analysis.

Because a single name can correspond to multiple salt forms and, in at least one case, multiple molecular identities, name-level trust is insufficient. Independent verification reduces to a concrete checklist: does the documentation state the salt form, is the mass consistent with that form, is purity reported with a disclosed method, and is the certificate tied to the specific lot? The July review does not change any of these analytical requirements.

The 23-24 July 2026 PCAC sessions, and any subsequent FDA action, will clarify regulatory status but will not substitute for analytical confirmation of identity and purity. ChemVerify will report the outcome strictly as a chemical-status and verification development.